// STATE LEGISLATION TRACKER

North Carolina HB 696: Medicaid and HHS Adjust./Other Critical Needs.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: North Carolina
Bill: HB 696
Session: 2025
Filed: 2025-04-02
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

HB696 became a broad North Carolina Medicaid and HHS budget/administration law. Based on the enacted text, it does not directly regulate compounded peptides, off-label prescribing, 503A/503B pharmacies, controlled substances, naturopathic or NP peptide prescribing, or PDMP rules.

Key Points

No direct change to compounded peptide access appears in the enacted bill.
No peptide-specific pharmacy, 503A, or 503B language was found.
Telehealth limits in the bill appear tied to Medicaid ABA therapy, not peptide care.
Medicaid cost-sharing and eligibility administration may matter only indirectly.
Do not treat this as a peptide-prescribing or compounding bill.

What to Watch For

Note Track any DHHS rulemaking under the law, but current enacted text does not target peptide prescribing or compounding.

Concern Medicaid copay and eligibility changes could indirectly affect low-income patients' broader care access.

Note The prompt's 'Filed' status appears outdated; the bill is now listed as Session Law 2026-1.

Where the Bill Stands

North Carolina lists HB696 as Session Law 2026-1, chaptered on April 30, 2026, so it is no longer merely filed.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws